Germany backed away from a variable discount pricing plan for branded drugs after industry pushback, Reuters reported—switching instead to a fixed approach. The original proposal was designed to reduce drug spending via higher markdowns tied to a variable structure. Industry leaders warned it could lead to investment pullbacks, with at least some major companies publicly flagging planned spending reductions. The change keeps pricing reform on the policy agenda, but the shift in mechanism may alter how quickly innovators adjust market access, tender strategies, and EU portfolio economics.